Stem Cell Innovations, Inc. has announced that the Company and TNO will collaborate in a program sponsored by a Dutch government EZ-Co-financing grant. The Parties have developed and will explore new strategies to control human stem cell differentiation into cartilage and cardiomyocytes.
“TNO has an impressive track record in combining fundamental disease biology research with developing new applications”, said Stem Cell Innovations’ CEO Dr. James Kelly. “Collaborating with them on further expansion of our industrialised human cell models will significantly strengthen SCI’s tailored drug discovery offerings”.
“We are very pleased with the collaboration of Stem Cell Innovations in this EZ-CO Financing awarded project” says Niek Snoeij, Director of Business Development, TNO “Getting access to their PluriCells and human stem cell biology expertise will leverage our internal capabilities. Further, this project fits nicely within TNO’s corporate program New Initiative Tissue Engineering”.
Stem Cell Innovations has produced seventeen lines of human pluripotent stem cells. These proprietary human PluriCell lines display many of the usual characteristics of human ES cells, including the ability to differentiate into cell types of the three germ layers. Therefore they have numerous applications in the drug discovery process: target and molecule discovery and validation, toxicology testing, and cell-based therapeutics.
In addition, PluriCells are cultured in a defined medium directly onto tissue culture plastic without the use of feeder layers, making them ideally suited for commercial high-throughput research applications.